Interim results for phase 1b dose expansion of Mtl-Cebpa in combination with pembrolizumab in patients with advanced solid tumour malignancies
Authors
Plummer, R.Sodergren, M.
Ryan, B.
Tachkov, I.
Reebye, V.
Meyer, T.
Pinato, D.
Sarker, D.
Basu, B.
Blagden, S.
Cook, Natalie
Evans, J.
Yachnin, J.
Chee, C. E.
Li, D. N.
El-Khoueiry, A.
Diab, M.
Huang, K. W.
D'Alessio, A.
Fulgenzi, C.
Noel, M.
Keenan, B.
Mahalingam, D.
Raulf, N.
Hogson, R.
Tan, C. P.
Nicholls, J.
Adderkin, A.
Vassiliadou, J.
Habib, R.
Rossi, J.
Habib, N.
Affiliation
Newcastle University, Newcastle-upon-Tyne,Issue Date
2022
Metadata
Show full item recordCitation
Plummer R, Sodergren M, Ryan B, Tachkov I, Reebye V, Meyer T, et al. Interim Results for Phase 1b Dose Expansion of Mtl-Cebpa in Combination with Pembrolizumab in Patients with Advanced Solid Tumour Malignancies. Journal for immunotherapy of cancer. 2022 Nov;10:A888-A9. PubMed PMID: WOS:000919423400804.Journal
Journal for Immunotherapy of CancerDOI
10.1136/jitc-2022-SITC2022.0850Additional Links
https://dx.doi.org/10.1136/jitc-2022-SITC2022.0850Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/jitc-2022-SITC2022.0850